• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.非酒精性脂肪性肝病中的细胞凋亡:诊断和治疗意义。
Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):201-12. doi: 10.1586/egh.11.6.
2
Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease.病态肥胖患者的肝和外周组织中的细胞凋亡和胰岛素抵抗与非酒精性脂肪性肝病的不同阶段有关。
Diabetologia. 2011 Jul;54(7):1788-98. doi: 10.1007/s00125-011-2130-8. Epub 2011 Apr 1.
3
A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.大鼠胰岛素抵抗和非酒精性脂肪性肝炎模型:过氧化物酶体增殖物激活受体-α及n-3多不饱和脂肪酸治疗对肝损伤的作用
Am J Pathol. 2006 Sep;169(3):846-60. doi: 10.2353/ajpath.2006.050953.
4
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.非酒精性脂肪性肝病与肝纤维化分期。
Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18.
5
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.非酒精性脂肪性肝病:从非酒精性脂肪性肝病到非酒精性脂肪性肝炎的进展中的基本发病机制。
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
6
Role of ceramides in nonalcoholic fatty liver disease.神经酰胺在非酒精性脂肪性肝病中的作用。
Trends Endocrinol Metab. 2012 Aug;23(8):365-71. doi: 10.1016/j.tem.2012.04.005. Epub 2012 May 17.
7
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.非酒精性脂肪性肝病中的脂毒性:并非所有脂质都是相同的。
Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):445-51. doi: 10.1586/egh.09.32.
8
The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.美国生活方式引起的肥胖综合征饮食在雄性和雌性啮齿动物中再现了非酒精性脂肪性肝病和非酒精性脂肪性肝炎的临床和转录组特征。
Am J Physiol Gastrointest Liver Physiol. 2020 Sep 1;319(3):G345-G360. doi: 10.1152/ajpgi.00055.2020. Epub 2020 Aug 5.
9
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.替米沙坦减轻小鼠脂肪性肝炎的进展:肝脏巨噬细胞浸润的作用及对脂肪组织的影响。
Liver Int. 2009 Aug;29(7):988-96. doi: 10.1111/j.1478-3231.2009.02006.x. Epub 2009 Apr 6.
10
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中的内脏脂肪组织内脏素。
Ann Hepatol. 2010 Jul-Sep;9(3):266-70.

引用本文的文献

1
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD.多面手人类抗原R(HuR):肝脏代谢和代谢相关脂肪性肝病中的关键角色
Livers. 2025 Sep;5(3). doi: 10.3390/livers5030033. Epub 2025 Jul 21.
2
Non-alcoholic fatty liver disease: Role of PNPLA3 and its association with environmental chemicals.非酒精性脂肪性肝病:PNPLA3的作用及其与环境化学物质的关联
Arch Clin Toxicol (Middlet). 2024;6(1):21-32. doi: 10.46439/toxicology.6.029.
3
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.细胞外囊泡介导的非酒精性脂肪性肝炎诊断与治疗方法:当前进展与未来展望
Lipids Health Dis. 2025 Jan 7;24(1):5. doi: 10.1186/s12944-024-02396-3.
4
Ubiquitination and Metabolic Disease.泛素化与代谢疾病。
Adv Exp Med Biol. 2024;1466:47-79. doi: 10.1007/978-981-97-7288-9_4.
5
Contribution of extracellular vesicles to steatosis-related liver disease and their therapeutic potential.细胞外囊泡在脂肪变性相关肝病中的作用及其治疗潜力。
World J Hepatol. 2024 Sep 27;16(9):1211-1228. doi: 10.4254/wjh.v16.i9.1211.
6
HY7207 Alleviates Hepatic Steatosis, Inflammation, and Liver Fibrosis in Mice with Non-Alcoholic Fatty Liver Disease.HY7207 减轻非酒精性脂肪性肝病小鼠的肝脂肪变性、炎症和肝纤维化。
Int J Mol Sci. 2024 Sep 12;25(18):9870. doi: 10.3390/ijms25189870.
7
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.非酒精性脂肪性肝病/代谢功能障碍相关脂肪性肝病的新药治疗流程
J Clin Transl Hepatol. 2024 Sep 28;12(9):802-814. doi: 10.14218/JCTH.2024.00123. Epub 2024 Jul 31.
8
The newly proposed plasma-glycosylated hemoglobin A1c/High-Density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination population.新提出的血浆糖化血红蛋白 A1c/高密度脂蛋白胆固醇比值可作为筛查代谢相关性脂肪性肝病的简单实用指标:一项基于体检人群的观察性研究。
BMC Gastroenterol. 2024 Aug 19;24(1):274. doi: 10.1186/s12876-024-03362-0.
9
Hepatocyte-specific loss of melanocortin 1 receptor disturbs fatty acid metabolism and promotes adipocyte hypertrophy.黑皮质素 1 受体在肝细胞中的特异性缺失会扰乱脂肪酸代谢并促进脂肪细胞肥大。
Int J Obes (Lond). 2024 Nov;48(11):1625-1637. doi: 10.1038/s41366-024-01600-9. Epub 2024 Aug 8.
10
Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis.肝细胞程序性细胞死亡:代谢功能障碍相关脂肪性肝炎中炎症和纤维化的触发因素。
Front Cell Dev Biol. 2024 Jul 12;12:1431921. doi: 10.3389/fcell.2024.1431921. eCollection 2024.

本文引用的文献

1
The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.泛半胱天冬酶抑制剂恩瑞卡森(IDN-6556)可减轻非酒精性脂肪性肝炎小鼠模型中的肝损伤和纤维化。
Liver Int. 2015 Mar;35(3):953-66. doi: 10.1111/liv.12570. Epub 2014 Jun 6.
2
Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis.Caspase-1 介导体脂性肝炎中纤维化的形成。
Lab Invest. 2012 May;92(5):713-23. doi: 10.1038/labinvest.2012.45. Epub 2012 Mar 12.
3
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.己酮可可碱改善非酒精性脂肪性肝炎:一项随机安慰剂对照试验。
Hepatology. 2011 Nov;54(5):1610-9. doi: 10.1002/hep.24544. Epub 2011 Aug 24.
4
An apoptosis panel for nonalcoholic steatohepatitis diagnosis.用于非酒精性脂肪性肝炎诊断的凋亡panel。
J Hepatol. 2011 Jun;54(6):1224-9. doi: 10.1016/j.jhep.2010.08.023. Epub 2011 Feb 12.
5
A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.一种包含代谢综合征、丙氨酸氨基转移酶和细胞角蛋白-18 的新复合模型,用于诊断病态肥胖患者的非酒精性脂肪性肝炎。
Aliment Pharmacol Ther. 2010 Dec;32(11-12):1315-22. doi: 10.1111/j.1365-2036.2010.04480.x. Epub 2010 Oct 7.
6
Obesity affects the liver - the link between adipocytes and hepatocytes.肥胖会影响肝脏——脂肪细胞和肝细胞之间的联系。
Digestion. 2011;83(1-2):124-33. doi: 10.1159/000318741. Epub 2010 Nov 1.
7
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD.血清 CK18M30 和瘦素水平可有效预测儿童非酒精性脂肪性肝病的脂肪性肝炎和纤维化。
J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):500-6. doi: 10.1097/MPG.0b013e3181e376be.
8
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo.还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶 2 在体内星状细胞激活和肝纤维化形成中起关键作用。
Gastroenterology. 2010 Oct;139(4):1375-84. doi: 10.1053/j.gastro.2010.05.074. Epub 2010 Jun 1.
9
Hepatocyte death: a clear and present danger.肝细胞死亡:一个明显而现实的危险。
Physiol Rev. 2010 Jul;90(3):1165-94. doi: 10.1152/physrev.00061.2009.
10
Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.在已建立的脂肪变性和非酒精性脂肪性肝炎动物模型中,泛半胱天冬酶抑制的影响。
J Hepatol. 2010 Sep;53(3):542-50. doi: 10.1016/j.jhep.2010.03.016. Epub 2010 May 26.

非酒精性脂肪性肝病中的细胞凋亡:诊断和治疗意义。

Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.

机构信息

Department of Pediatric Gastroenterology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

出版信息

Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):201-12. doi: 10.1586/egh.11.6.

DOI:10.1586/egh.11.6
PMID:21476915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3119461/
Abstract

Pathological increases in cell death in the liver as well as in peripheral tissues has emerged as an important mechanism involved in the development and progression of nonalcoholic fatty liver disease (NAFLD). An increase in hepatocyte cell death by apoptosis is typically present in patients with NAFLD and in experimental models of steatohepatitis, while an increase in adipocyte cell death in visceral adipose tissue may be an important mechanism triggering insulin resistance and hepatic steatosis. The two fundamental pathways of apoptosis, the extrinsic (death receptor-mediated) and intrinsic (organelle-initiated) pathways, are both involved. This article summarizes the current knowledge related to the distinct molecular and biochemical pathways of cell death involved in NAFLD pathogenesis. In particular, it will highlight the efforts for the development of both novel diagnostic and therapeutic strategies based on this knowledge.

摘要

肝脏以及外周组织中细胞死亡的病理性增加,已成为非酒精性脂肪性肝病 (NAFLD) 发生和进展的一个重要机制。在非酒精性脂肪性肝病患者和脂肪性肝炎的实验模型中,肝细胞凋亡的增加通常存在,而内脏脂肪组织中脂肪细胞死亡的增加可能是触发胰岛素抵抗和肝脂肪变性的一个重要机制。凋亡的两条基本途径,即外在(死亡受体介导)和内在(细胞器起始)途径,都参与其中。本文总结了与 NAFLD 发病机制相关的细胞死亡的不同分子和生化途径的现有知识。特别是,它将强调基于这些知识开发新的诊断和治疗策略的努力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/db7118d2e67d/nihms295562f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/10446ef7d5a3/nihms295562f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/e333a8c545f7/nihms295562f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/db7118d2e67d/nihms295562f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/10446ef7d5a3/nihms295562f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/e333a8c545f7/nihms295562f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d6a/3119461/db7118d2e67d/nihms295562f3.jpg